

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1498)

**APPOINTMENT OF CHIEF FINANCIAL OFFICER AND
RE-DESIGNATION OF CHIEF FINANCIAL AND OPERATING OFFICER
AS GENERAL MANAGER OF CLINIC SEGMENT**

The board (the “**Board**”) of directors of PuraPharm Corporation Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) announces that Mr. Lau Ka Kuen (“**Mr. Lau**”) has been appointed as the Chief Financial Officer of the Company with effect from 24 September 2018. Meanwhile, Ms. Li Wai Shan (“**Ms. Li**”) has been re-designated from Chief Financial and Operating Officer of the Company to General Manager of the Group’s clinic segment with effect from 24 September 2018.

Mr. Lau will be responsible for the Group’s overall financial reporting and management, corporate finance and investment activities, investor relations and company secretarial matters.

Ms. Li will be responsible for the overall operation and development of the Group’s clinic segment. Before re-designation of Ms. Li, Mr. Chan Lung Sang, a former executive director of the Company, was responsible for the overall operation and development of the Group’s clinic segment until his retirement on 25 May 2018.

Mr. Lau, aged 36, joined the Group in 2013 and is currently the Group Financial Controller and company secretary of the Company. Prior to joining the Group from 2005 to 2011, Mr. Lau was the staff accountant, associate, senior auditor and later on an audit manager in Deloitte Touche Tohmatsu, Hong Kong, a certified public accounting firm in Hong Kong, where he was primarily responsible for audit of companies listed on The Stock Exchange of Hong Kong Limited. Mr. Lau was accredited as a chartered public accountant by the Hong Kong Institute of Public Accountants in 2007 and a chartered financial analyst by the Chartered Financial Analyst Institute in 2014. He obtained a bachelor’s degree in business administration in finance and information system from the Hong Kong University of Science and Technology in 2005.

The Board would like to take this opportunity to welcome Mr. Lau and Ms. Li in taking up their new roles in the Company.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 24 September 2018

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, and Ms. Man Yee Wai, Viola; the non-executive director of the Company is Mr. Chow Stanley; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.